Research and development (includes 8,721 and 11,099 of share-based compensation expense for the three months ended june 30, 2026 and 2025, respectively)
202,016
198,945
165,380
164,568
Acquired in-process research and development
-
0
-
-
General and administrative (includes 74,621 and 71,079 of share-based compensation expense for the three months ended june 30, 2026 and 2025, respectively)
165,527
158,250
175,072
143,125
Total operating expenses
367,827
357,515
341,152
307,804
Gain on sale of telavant net assets
-
0
0
0
Gain on litigation settlement
392
770,235
-
-
Gain from operations
-365,993
415,240
-339,153
-306,233
Change in fair value of investments
36,637
-25,922
21,592
128,501
Change in fair value of liability instruments
0
-48,832
24,416
-20,959
Gain on deconsolidation of subsidiaries
-
2,757*
-
-
Interest income
36,922
98,282*
43,266
45,341
Other expense, net
-2,130
12,572
8,342
-5,694
Gain before income taxes
-294,564
454,097
-290,369
-159,044
Income tax (benefit) expense
-3,958
98,353
23,332
6,995
(gain) income from continuing operations, net of tax
-
355,744
-313,701
-166,039
Income (loss) from discontinued operations, net of tax
-
0
0
0
Net gain
-290,606
355,744
-313,701
-166,039
Net gain attributable to noncontrolling interests
-100,769
52,750
-47,810
-52,520
Net gain attributable to roivant sciences ltd
-189,837
302,994
-265,891
-113,519
Basic EPS
-0.26
0.422
-0.38
-0.17
Diluted EPS
-0.26
0.422
-0.38
-0.17
Basic Average Shares
720,776,739
717,363,650
696,859,682
680,947,866
Diluted Average Shares
720,776,739
717,363,650
696,859,682
680,947,866
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.